Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
6 search results for:

289 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 12-12-2022 | SABCS 2022 | Conference coverage | Article

    Phase 3 data support add-on capivasertib in people with AI-resistant advanced breast cancer

    The other primary endpoint of the trial – PFS in the 289 participants with AKT pathway alterations (most commonly PIK3CA mutations) – also significantly favored the capivasertib group, at a median of 7.3 months compared with 3.1 months in the placebo group.

    Author:
    Shreeya Nanda
    Published in:
    SABCS 2022; San Antonio, Texas, USA: 6–10 December
  2. 26-10-2022 | Breast cancer | News | Article

    Minimal access breast surgery ‘valid’ option for early breast cancer

    After propensity score matching to minimize selection bias, the team analysed data for 603 women who underwent endoscopic (n=289), endoscopy-assisted (n=302) or robot-assisted (n=12) procedures, and 1809 women who underwent conventional surgery.

    Author:
    Lynda Williams
    Published in:
    JAMA Surg 2022; doi:10.1001/jamasurg.2022.4711
  3. 10-02-2022 | Prostate cancer | News | Article

    Niraparib promising in patients with mCRPC and DNA repair gene defects

    The GALAHAD study included 289 men who had progressed after treatment with at least one androgen signaling inhibitor and taxane (63% had received three or more prior lines of therapy), and had germline or biallelic pathogenic alterations in BRCA1 or BRCA2 or in other prespecified non- BRCA genes, namely ATM , BRIP1 , CHEK2 , FANCA , HDAC2 , or PALB2 .

    Author:
    Shreeya Nanda
    Published in:
    Lancet Oncol 2022; doi:10.1016/ S1470-2045(21)00757-9
  4. 02-04-2019 | Advanced breast cancer | Editorial | Article

    The use of CDK4/6-inhibitors in advanced, hormone-receptor positive breast cancer: why, when and who?

    On 1st February 2019, 289 patients were randomized.

    Author:
    Annemiek van Ommen - Nijhof, Gabe S Sonke, Inge R Konings, Agnes Jager
  5. 01-12-2015 | Hematologic cancers | Article

    Molecular therapy for acute myeloid leukaemia

    This trial included 289 patients with  NPM1  mutations 28 .

    Author:
    Catherine C. Coombs, Martin S. Tallman, Ross L. Levine
  6. 14-04-2015 | Renal cell carcinoma | Article

    Tumor and patient factors in renal cell carcinoma—towards personalized therapy

    TCGA Research Network identified 289 genes that were epigenetically silenced in at least 5% of ccRCC tumours. 5  The top-ranked hypermethylated gene (observed in 36% of tumours) was  UQCRH , which has been previously proposed as a tumour suppressor gene. 56  This gene has not been identified in previous methylation studies in RCC.

    Author:
    Ahmed Q. Haddad, Vitaly Margulis
  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.